key: cord-0851790-irn4wfm7
authors: Onnis, Carlotta; Muscogiuri, Giuseppe; Paolo Bassareo, Pier; Cau, Riccardo; Mannelli, Lorenzo; Cadeddu, Christian; Suri, Jasjit S; Cerrone, Giulia; Gerosa, Clara; Sironi, Sandro; Faa, Gavino; Carriero, Alessandro; Pontone, Gianluca; Saba, Luca
title: Non-invasive coronary imaging in patients with COVID-19: a narrative review()
date: 2022-02-01
journal: Eur J Radiol
DOI: 10.1016/j.ejrad.2022.110188
sha: 15134b14fbfb523fd5cd0e51850ce9d5a6b71578
doc_id: 851790
cord_uid: irn4wfm7

SARS-CoV-2 infection, responsible for COVID-19 outbreak, can cause cardiac complications, worsening outcome and prognosis. In particular, it can exacerbate any underlying cardiovascular condition, leading to atherosclerosis and increased plaque vulnerability, which may cause acute coronary syndrome. We review current knowledge on the mechanisms by which SARS-CoV-2 can trigger endothelial/myocardial damage and cause plaque formation, instability and deterioration. The aim of this review is to evaluate current non-invasive diagnostic techniques for coronary arteries evaluation in COVID-19 patients, such as coronary CT angiography and atherosclerotic plaque imaging, and their clinical implications. We also discuss the role of artificial intelligence, deep learning and radiomics in the context of coronary imaging in COVID-19 patients.

Cardiovascular diseases (CVDs) are the leading cause of death worldwide. Among CVDs, ischemic heart disease is responsible for 16% of the world's total deaths [1] [2] . Even though it is widely assumed that the incidence of myocardial infarction (MI) is related to traditional cardiovascular (CV) risk factors, it is known that the risk of MI increases during acute infections, such as influenza [3] . More recently, laboratory tests showed that the highest risk occurs within the first three days of influenza [4] .

The infection caused by SARS-CoV-2, declared global pandemic by WHO in March 2020, is responsible for a potentially fatal syndrome called COVID-19, which is mainly a respiratory disease, but it can also have cardiac complications with worsening prognosis [5] .

The pathophysiological mechanisms underlying cardiac involvement can be summarized as follows:

1. The respiratory syndrome can cause severe hypoxemia with consequent multi-organ failure and cardiac injury [6] 2. SARS-CoV-2 binds to ACE2 to gain intracellular entry; this can cause endothelial dysfunction and myocardial damage [7] 3. SARS-CoV-2 increases inflammation by stimulating the release of cytokines (IL-6, IL-1B and TNF) and chemokines (CCL-2, CCL-3 and CCL-5) from respiratory epithelial cells, dendritic cells (DCs) and macrophages [8] . SARS-CoV-2 also promotes accumulation of epicardial adipose tissue (EAT) and perivascular adipose tissue (PVAT). This leads to local vascular inflammation by paracrine signaling, causing endothelial disfunction, plaque formation and deterioration [9] . EAT and PVAT, in turn, sustain systemic inflammation by cytokine-release into the general circulation [10] . In COVID-19 patients, the severity of the cytokine storm has been recognized as an important factor in predicting the clinical course of extrapulmonary organ failure and mortality [11] . In addition, high levels of pro-inflammatory cytokines may lead to macrophage infiltration of the myocardium [12] .

Any of these mechanisms may exacerbate underlying pathological cardiovascular conditions, promoting plaque vulnerability, leading to increased risk of acute coronary syndrome (ACS) [13] [14] .

An increase of troponin serum levels has been observed in 8-12% of COVID-19 patients, which is associated with higher mortality [15] . In general, ACS is due to inflammation, rupture or erosion of the plaque, causing acute thrombosis of the atherosclerotic plaque [16] . Moreover, the vulnerability of the plaque has broader clinical implications [17] . SARS-CoV-2 infection can promote/determine coronary atherosclerotic plaque vulnerability: high levels of pro-inflammatory cytokines and chemokines can lead to thrombus formation, inducing either tissue factor secretion or coronary vasospasm, which increase shear stress and lead to platelet activation [18] . Increased inflammation can also induce neutrophil and monocyte activation, which is responsible for endothelial damage, rupture of the fibrous cap of the plaque and consequent thrombus formation. Furthermore, CD4+ T cells stimulate smooth muscle cells to migrate into the intima and generate collagen and fatty streaks, facilitating the progression of atherosclerotic lesions [19] . PVAT/EAT involvement in atherogenesis and CAD is a well-known process, supported by in vitro, ex vivo, animal and clinical studies. These reports highlight how adipose tissue can secrete and express adipokines and cytokines, cause inflammation [20] , and clarify the outside-in signaling in vascular pathophysiology [21] . Moreover, SARS-CoV-2 both disseminates into PVAT through viremic blood stream and induces PVAT inflammation and consequent activation via the systemic cytokine-storm [22] .

Acute infections such as COVID-19 can lead to both type 1 and type 2 MI: the former due to thin-cap rupture, which leads to inflammatory cells and fibrin release into the lumen, causing platelets, neutrophils and fibrin accumulation, responsible for acute obstruction of coronary arteries. The latter, due to acute stressors in patients with stable known or presumed CAD, which lead to higher oxygen demand resulting in insufficient blood flow to the ischemic myocardium to meet the increased myocardial oxygen demand. In particular, an acute infection may lead to IL-1, TNF- and catecholamines' release resulting in a mismatch between oxygen supply and demand [23] . Moreover, in addition to type 1 and type 2 MI, in COVID-19 patients there has been an increased incidence of MINOCA (myocardial infarction with non-obstructive coronary arteries) [24] which includes plaque (causing <50% stenosis) rupture or erosion, coronary embolism and dissection, and coronary artery spasm. From a clinical point of view, differential diagnosis between different causes of ACS and acute cardiac injury in patients with COVID-19 can be difficult [25] [26] . In this setting, after excluding type 1 MI with coronary angiography demonstrating a culprit lesion, non-invasive cardiac imaging represents a useful diagnostic tool. (Table 1) Even though the role of imaging remains controversial and varies depending on country and institution [27] , it has been recommended worldwide the use of imaging (computed tomography (CT) or chest radiography if the access to CT is limited) in patients with moderate to severe features of COVID-19, regardless of test results, and in positive patients with worsening respiratory status [28] .

Thus, chest CT is a key tool for diagnosis and staging of COVID-19, but it can also give relevant information regarding extra-pulmonary manifestations. Precisely, as regards to cardiovascular involvement, the role of cardiovascular CT (CCT) in COVID-19 is continuously under investigations, with new data appearing monthly as noted in "The Journal of Cardiovascular Computer Tomography: 2020 Year in review" [29] ; the exact clinical indications when to use CT or cardiac magnetic resonance (CMR) are yet to be defined but they both have promising implications in clinical practice. With regards to CCT, it can be used to evaluate coronary artery calcification (CAC), which can be easily detected during scans, and which seems to be an integrative marker of worse prognosis in patients with COVID-19 without previous CV disease. Dillinger et al. [30] evaluated 209 patients with no history of CVD who underwent CT within 24 hours of admission. The median age was 62 years and CAC was detected in 106 patients (CAC+ patients = 50.7%). 50.0% of CAC+ subjects had primary outcome (first occurrence of noninvasive or invasive mechanical ventilation, ECMO, or death within 30 days after admission), compared to 17.5% of CAC-patients.

Hence, CAC was significantly associated with the primary outcome, even in multivariate analysis, suggesting that the presence and extent of CAC are associated with a worse prognosis. Similarly, a smaller study by Nai Fovino et al. [31] evaluated 53 hospitalized COVID-19 patients without known coronary artery disease (CAD), who underwent CT, in which CAC score was calculated. In this study, the endpoints were in-hospital mortality and intensive care unit admission. A significant increase was found among patients with high (>400) CAC score, suggesting that CAC might be a helpful tool to stratify patients, and identify those at higher risk of worse outcome.

Moreover, Scoccia et al. [32] tested the hypothesis that combining clinical history with CAC score routinely could stratify prognosis of COVID-19 patients, studying in-hospital mortality and inhospital myocardial infarction and cerebrovascular accident (MI/CVA) as primary and secondary endpoints respectively. They divided patients into three groups: clinical CAD (with a positive history), subclinical CAD (with CAC>0) and no CAD (CAC =0). This study found a significant increase of both in-hospital mortality and MI/CVA rates among patients with clinical and subclinical CAD. In addition, through an area under the curve improvement, a multivariate model with "CAD stratification" was found to be superior to a model based on the clinical cardiovascular risk profile.

Thus, this study suggests that CAC score might be a useful tool to complement COVID-19 risk stratification tools. Moreover, the presence and extension of CAD, assessed by CAC, appears as a better parameter than clinical cardiovascular risk assessment for COVID-19 prognosis.

In case of diagnosed or suspected cardiac complications, cardiac imaging is indicated, especially when it is likely to substantially change patient management or be lifesaving [33] . To evaluate CAD, coronary CT angiography (CCTA) is the preferred non-invasive imaging modality since it reduces exposure time of patients and personnel ( Figure 1 ). Taken into account that patients with COVID-19 and CV risk factors have higher morbidity and mortality [34] , CCTA represents a valid imaging modality for assessment of patients with chronic coronary syndromes. It can also exclude or confirm an ACS in COVID-19 pneumonia with elevated troponin serum levels [33] .

Moreover, because NSTEMI management depends on the patient CV risk, CCTA can speed-up risk stratification. In particular, as Licu et al. [35] showed in their study, CCTA can also identify the phenotype of vulnerable plaques at higher risk of rupture, leading to future ACS ( Figure 2 ). Presence of low attenuation (focal central area of plaque with attenuation density of <30 HU), positive remodeling (outer vessel diameter 10% greater than the mean diameter of the segments immediately proximal and distal to the plaque), spotty calcification (focal calcification within the vessel wall <3 mm in maximum diameter) and napkin-ring sign (central area of low attenuation surrounded by a ring-shaped area of higher attenuation representing lipid-rich atheroma) seem to be the CCTA features of atheromatous plaques producing ACS ( Table 2 ). The presence of these features identifies very high-risk plaques, thus, very high-risk patients, who might benefit from primary or secondary prevention. The former with healthy diet, exercise, smoking cessation and effective hypolipidemic therapy. The latter, in case of symptomatic patients, could be obtained with rapid invasive coronary angiography. In the scenario of primary prevention, plaque features on CCTA may be used to facilitate the allocation of more aggressive and costly treatment regimens (e.g. new hypolipidemic or anti-inflammatory agents) to selected patients, depending on the underlying mechanism of atherosclerosis, resulting in a tailored management of ACS.

While little has changed in the management of STEMI during COVID-19 pandemic [36] , for NSTE-ACS the European Society of Cardiology recommends non-invasive testing for patients included among intermediate and low risk categories, favoring CCTA if equipment and expertise are available in order to shorten hospital stay [37] . As the VERDICT trial shows, CCTA is a valid imaging modality, able to rule out clinically significant CAD (stenosis >50%) in NSTE-ACS, with its negative predictive value of 90.9% and positive predictive value of 87.9%. Thus, the trial suggests that CCTA should be utilized to quickly identify patients in whom invasive testing will be futile. The implications are multiple and of great relevance: a clinical impact, reducing the duration of antithrombotic medical therapy; a safety impact for COVID-19 containment, avoiding unnecessary exposure and shortening hospitalization [38] ; an economic impact, considering that over a lifetime, CCTA is cost effective because it allows an early and accurate detection of true CAD status, reducing mortality thanks to a more appropriate preventive medical therapy [39] .

For patients with low pre-test probability, CCTA may be combined with myocardial late iodine enhancement (LIE), in order to detect myocardial inflammation, fibrosis or diffuse ischemia [40] . Even though cardiac MRI with late gadolinium enhancement (LGE) is the gold standard to detect myocardial fibrosis/edema/necrosis, LIE cardiac CT represents an effective alternative, particularly because of its fast acquisition times, accessibility and suitability for patients for whom MRI is contraindicated. In their study, Oda et al. [41] showed excellent agreement between MRI-

LGE and CT-LIE; for this reason, they suggested that cardiac CT can assess late enhancing lesions with results comparable to those obtained with cardiac MRI, giving adequate information about myocardial characterization. Similarly, Otha et al. assessed the diagnostic performance of dualenergy CT with myocardial LIE using MRI-LGE as standard of reference and they obtained high accuracy, high diagnostic performance and excellent agreement [42] . In the context of SARS-CoV-2 infection, LIE can be a valuable additional tool, especially when MRI cannot be performed because of its long examination time which results in long exposure time. As Pontone et al. [43] showed in a single-case report and further explained in their review [44] , in patients with COVID-19 specific scan protocols for CT allow to identify pneumonia and obstructive CAD (dual rule out), as well as pulmonary embolism (triple rule out) and also myocarditis through LIE, creating the new concept of quadruple rule out (Figure 3-4 ). In addition, as Feuchtner et al. [45] suggested in a single-case report, CCTA can also show suggestive findings for vasculitis, which may trigger endothelial dysfunction and vasospasm, explaining MINOCA in the context of NSTE-ACS.

Since the advent of deep learning (DL)/machine learning (ML) techniques, there has been a huge and meaningful impact on radiology and cardiac radiology as well. In general, artificial intelligence (AI) technologies are those that make educated decisions regarding diagnosis, monitoring, treatment and management of a patient's condition. Among AI, ML architecture is a twostep process in which features are extracted and used within a training system to create offline coefficients, which are then transformed by test data giving an intelligent classification. Meanwhile, DL architecture is similar to a visual cortex that imitates multiple layers of neural network applied to image data to directly extract features and to characterize tissues [46] . As Litjens et al. [47] examined in their review, many types of DL algorithms can be applied to cardiovascular imaging, the most common being convolutional neural networks (CNNs). CNNs are a type of artificial neural networks commonly used in image analysis, especially when the tasks required are classification (for example plaque risk assessment), regression (e.g. calcium scoring) or anatomical segmentation. Moreover, as Saba et al. [48] noted in their review, considering the rapid pace of growth of DL methods and their clinical and economic advantages, it is inevitable that they will have an increasingly relevant role in radiology.

In the COVID-19 pandemic setting, since the prevalence is high, AI, mainly with DL technologies, works well and represents a useful tool for diagnostic and prognostic purposes. Wang et al. [49] in their study proposed a fully automatic DL system that detects COVID-19 features on CT images, predicting the patient's probability of having COVID-19. They also stratified patients into high-risk and low-risk groups, identifying those who need urgent medical care. Thus, they suggested DL as a convenient tool for fast screening COVID-19. Moreover, in a study that compared six AI paradigms used to classify COVID pneumonia and non-COVID pneumonia, Saba et al. [50] showed that all six AI models successfully classified COVID pneumonia against non-COVID. In the same study, DL was shown to have higher accuracy than ML. Similar results have been obtained by Li et al. [51] who developed a 3D DL framework for COVID-19 detection. For a complete review on AIbased image analysis for COVID-19 see Dong et al. work [52] .

AI may be applied to CCTA as well. As Han et al. [53] assessed in their study, AI-based CCTA significantly reduces time for post-processing and diagnosis compared to traditional methods.

Moreover, CCTA-AI, when compared to traditional CCTA, appeared to have sensitivity of 88% versus 59%, accuracy of 86 versus 83% and negative predictive value of 94% versus 83% in identifying >50% of stenotic vessels. Similarly, Muscogiuri et al. [54] in their study tried to develop a CNN to classify CCTA in the correct CAD reporting and data system (CAD-RADS) category.

CAD-RADS classification is used to identify patients that may require further testing or invasive imaging, but also to evaluate the patient's prognosis. In this classification, the final score of CCTA is based on patient-based analysis, in which each vessel is evaluated using a scale from 0 (absence of stenosis) to 5 (total occlusion), with 4 being either stenosis between 70-99% or >50% left main or three vessels >70%. The main findings obtained are represented by the high diagnostic accuracy of CNN in differentiating patients with CAD-RADS 0 from those with CAD-RADS>0. Collectively, the application of the CAD-RADS classification allows ruling out CAD in a short time, and significantly decreases time of analysis for on-site physicians reading images compared to the CNN method.

The combination of CCTA and AI has been used to evaluate another promising non-invasive imaging marker, the perivascular fat attenuation index (FAI), a marker of adipocyte lipid content and size. In this field, considerable progress has been made by the study of Antonopoulos et al. [55] , who hypothesized that the PVAT phenotype might change depending on different degrees of inflammation. In this work, PVAT gradient was measured with CCTA and quantified by the transcriptomic profile using AI. They obtained promising results, indicating that FAI has great sensitivity and specificity for detecting tissue inflammation and predicting future cardiovascular events. In the context of COVID-19 pandemic, considering the role of PVAT in the pathophysiology of atherosclerosis and CAD, EAT/PVAT volume and attenuation, measured with CT, have been used as indicators of extent of pneumonia and predictors of adverse outcomes. As Grodecki et al. [56] showed in their study, EAT volume and attenuation, automatically quantified with a DL algorithm from 3D fat voxels between -190 and -30 HU, associate with quantitative burden of COVID-19 pneumonia and independently predict clinical deterioration or death. Moreover, Hui et al. [57] suggested that EAT, defined as fat within the pericardial sac, is associated with increased inflammatory cytokine expression in patients with CAD. They also showed in their study that EAT density, measured in a layer range between the bifurcation of pulmonary artery and the diaphragm, has lower values in severe and critical COVID-19 patients when compared to light and mild groups.

These findings suggest that low EAT density might be used as an indicator of cardiac inflammation in COVID-19 patients.

Among AI, recent research moved toward radiomics, a group of techniques in which highly abstract quantitative features are automatically extracted from medical images and then processed by statistical classifiers that select which features are relevant to the task. This method is particularly useful for coronary plaque characterization. Since coronary lesions are composed by different histologic components, each tissue will be depicted with different attenuation values on CT, giving quantitative image parameters, including shape, volume, heterogeneity, lesion length and remodeling index ( Figure 5 ). These characteristics have been shown to be predictive markers of future cardiac events [58] . During COVID-19 pandemic, this technique has been applied to PVAT in order to quantify inflammation. Kotanidis et al. [59] [60] AI can also be used for public health management. As Vaishya et al. [61] summarized in their review, AI can be applied for early detection of the infection, for monitoring and prediction of the spread of the virus, for contact tracing and for projection of cases and mortality.

The public health and economic burdens of CAD are substantial worldwide. Since the beginning of COVID-19 pandemic, even more importance should be given to CAD considering the impact on mortality and prognosis that this group of diseases has on COVID-19 patients [62] . As many authors studied and explained, SARS-CoV-2 infection and CAD are mutually linked: not only pre-existing chronic CAD is associated with worse clinical outcomes, but also SARS-CoV-2 itself is associated with a higher risk of atherosclerosis and greater plaque vulnerability leading to a deterioration of the patient's clinical condition. Thus, assessment of CAD is crucial in patients with CV risk factors presenting with COVID-19. In this context, non-invasive imaging techniques can play a valuable role in speeding-up risk stratification, while reducing exposure time to SARS-CoV-2.

The link between CAD and COVID-19 and its impact on patients who do recover from the infection has not been clarified yet. The Center of Disease Control and Prevention started reporting long-term effects of SARS-CoV-2: many patients continue to report cardiopulmonary symptoms (e.g. chest pain, dyspnea, fatigue), colloquially known as "long COVID", suggesting that the cardiovascular consequences of COVID-19 may extend beyond acute infection. Several registries and studies have been created to track the cardiac impact of the infection, but the results are still ongoing.

For example, the post hospitalization COVID-19 study of the British Heart Foundation (https://www.phosp.org) will follow-up patients with questionnaires, laboratory tests, functional tests, cardiac MRI and chest CT. The latter will analyze for evidence of inflammation in the heart and the use of AI will help quantifying its level, comparing it to the one calculated before and during infection.

As we can read in The Journal of Cardiovascular Computer Tomography: 2020 Year in review [29] , the field of CCTA advances at a remarkable pace with expanding clinical implications. Firstly, CAC score, assessed by CAC-DRS (Data and Reporting System), seems to have high prognostic accuracy, as well as CAD-RADS, which provides additional prognostic discrimination for prediction of future coronary heart diseases [63] . Moreover, using CAC score as a screening tool to assess CVD risk seems to have important consequences on treatment management. As Van der Aalst et al. [64] suggested in their study, CAC score compared to Systematic COronary Risk Evaluation (SCORE) classifies significantly fewer men and women at increased risk, thus less preventive treatment (ACEinhibitors + statins) is indicated in this asymptomatic population, which may increase compliance and decrease costs for unnecessary treatment.

In addition, now that considerable progress has been made towards a better management of COVID-19, ACS represents a serious concern currently affecting global healthcare. ACS incidence is trending downward worldwide, having important consequences and implications. The Italian Society of Cardiology registered, during the pandemic, a significant reduction of the 48,4% of MI incidence in a week (for both STEMI and NSTEMI), compared to the equivalent period in 2019.

Nevertheless, they observed an increase in STEMI fatality rate and complications during the pandemic compared to 2019 [65] . These data suggest that either patients are waiting longer between symptoms onset and hospital referral, or healthcare resources/medical effort are relocated to manage the pandemic, or both. Whichever the reason is, the consequences have great impact on global healthcare: late presenting MIs lead to chronic heart failure and sudden cardiac death, causing an increase of early and late morbidity and mortality. Thus, the global registration of lower rates of admitted and treated patients with ACS is a problem that has to be addressed. There are two possible ways to face it: promoting patients' compliance and education on ACS, in order to avoid unnecessary delays in STEMI management, such as symptom-to-door time, which during the pandemic is deeply influenced by patient perception and fear of contracting COVID-19. Secondly, with regards to NSTEMI, every attempt should be made to avoid clinicians' delayed or missed diagnosis. For this purpose, CCTA might be a useful tool to differentiate the causes of troponin-elevation and to identify patients who do not need invasive testing. In this setting, guidance and guidelines from international societies represent valuable tools to standardize protocols for management and treatment of ACS.

In line with the current recommendations from the European Society of Cardiology (ESC), the European Association of Cardiovascular Imaging (EACVI) and the Society of Cardiovascular Computed Tomography (SCCT), cardiac CT in COVID-19 patients should be limited to hospitalized patients, where it is likely to change patient management or be lifesaving [33, 37, 66] . In particular, CCTA is useful for, and should be reserved to, patients with low and intermediate risk of NSTE-ACS, in order to rule-out ACS without undergoing invasive coronary angiography (ICA), which is associated to higher risk for both the patient (procedural risks) and the healthcare providers (exposure risk). Thus, in the clinical setting, an ideal diagnostic algorithm might be performing a CCTA with a "quadruple rule-out" protocol and CAC score evaluation in patients with suspected or diagnosed COVID-19, who presents with chest pain/mild troponin increase/normal ECG or non-ST elevation, with low-to-intermediate CV risk, in order to quickly exclude the need of early invasive coronary angiography. In all the other cases of diagnosed SARS-CoV-2 infection, the mere CAC score evaluation might be included in routine chest-CT in order to better assess CV risk and COVID-19 prognosis.

Moreover, in the setting of ACS all efforts should be made to differentiate type 1 MI from type 2 MI and other causes of troponin elevation or ST changes, in order to avoid unnecessary ICA [67] . As Stefanini et al. [24] analyzed in their study, approximately 40% of their COVID-19 patients presenting with STEMI, did not have obstructive CAD and no culprit lesion was identifiable on ICA, excluding type 1 MI.

In this context, CCTA represents a valid clinical and diagnostic modality, thanks to its numerous advantages summarized as follows:

-Coronary CT Angiography (CCTA) is a rapid non-invasive imaging modality for cardiovascular risk evaluation in patients during and after exposure to COVID-19;

-CCTA with a 'quadruple rule out' protocol can identify pneumonia, pulmonary embolism, CAD and myocardial injury in acute chest pain;

-CCTA is a non-invasive imaging modality with high accuracy and high negative predictive value, enabling identification of acute coronary syndromes without ST-segment elevation (NSTE-ACS) for which invasive testing will be futile;

-Coronary artery calcification (CAC) seems a promising tool to evaluate CAD risks in COVID-

-CCTA has the potential to identify the phenotype of vulnerable plaques at higher risk of rupture and may be used to select patients at very-high risk for adequate invasive imaging; -Perivascular adipose tissue (PVAT) evaluated with CCTA may provide comprehensive information on inflammation grade and has the potential to provide predictive markers for pneumonia, in-hospital mortality and ICU admission;

-Artificial intelligence (AI) and deep learning (DL) algorithms provide tools to reduce postprocessing time and increase diagnostic accuracy.

However, CCTA has also some limitations: performing the exam in a symptomatic COVID-19 patient may be difficult, due to tachycardia and lack of breath-hold, leading to the need of beta-blockade and adjustment of the scanning protocol, in order to ensure optimal image quality and accurate diagnosis.

That's because CCTA should be performed only in equipped and qualified centers. Even though CCTA is not free of challenges, it is a well-established, effective imaging technique, which can be extremely useful during COVID-19 pandemic, particularly in the context of coronary artery diseases.

The role of this promising imaging modality should be further evaluated in studies based on large numbers of patients. 

-Coronary CT Angiography (CCTA) represents a rapid non-invasive imaging technique for cardiovascular risk evaluation in patients during and after exposure to SARS-CoV-2;

-CCTA with a 'quadruple rule out' protocol can identify pneumonia, pulmonary embolism, CAD and myocardial injury in acute chest pain;

-CCTA has high accuracy and high negative predictive value, enabling identification of acute coronary syndromes without ST-segment elevation (NSTE-ACS) for which invasive testing will be futile;

-Coronary artery calcification (CAC) seems a promising tool to evaluate CAD risks in COVID-

-CCTA has the potential to identify the phenotype of vulnerable plaques at higher risk of rupture and may be used to select patients at very-high risk for adequate invasive imaging;

-Perivascular adipose tissue (PVAT) evaluated with CCTA may provide comprehensive information on inflammation grade and has the potential to provide predictive markers for pneumonia, in-hospital mortality and ICU admission;

-Artificial intelligence (AI) and deep learning (DL) algorithms provide tools to reduce postprocessing time and increase diagnostic accuracy.

Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study

Retrieved from who

Excess mortality from causes other than influenza and pneumonia during influenza epidemics

Risk of myocardial infarction and stroke after acute infection or vaccination

Association of cardiac injury with mortality in . hospitalized patients with COVID-19 in Wuhan, China

Clinical features of patients infected with 2019 novel coronavirus in

COVID-19 and the cardiovascular system

Chemokine up-regulation in SARS-coronavirus-infected, monocyte-derived human dendritic cells

Imaging Cardiovascular Inflammation in the COVID-19 Era

The epicardial adipose tissue and the coronary arteries: dangerous liaisons

The cytokine storm and factors determining the sequence and se-verity of organ dysfunction in multiple organ dysfunction syndrome

Pathological features of COVID-19-associated myocardial injury: a multicentre cardiovascular pathology study

Coronaviruses and the cardio-vascular system: acute and long-term implications

Can COVID19 trigger the plaque vulnerability-a Kounis syndrome warning for "asymptomatic subjects". Cardiovasc Diagn Ther

Myocardial injury and COVID-19: Possible mechanisms

Mechanisms of Acute Coronary Syndromes and Their Implications for Therapy

From Vulnerable Plaque to Vulnerable Patient: A Call for New Definitions and Risk Assessment Strategies: Part I

Possible mechanisms responsible for acute coronary events in COVID-19

Role of acute infection in triggering acute coronary syndromes

Perivascular adipose tissue as a cause of atherosclerosis

Perivascular Adipose Tissue and Vascular Perturbation/Atherosclerosis

Coronary microvascular dysfunction pathophysiology in COVID-19

Microcirculation

Acute Infection and Myocardial Infarction

ST-elevation myocardial infarction in patients with COVID-19: clinical and angiographic outcomes

Acute myocardial injury, MINOCA, or myocarditis? Improving characterization of coronavirus-associated myocardial involvement

COVID-19 Imaging: What We Know Now and What Remains Unknown

The Role of Chest Imaging in Patient Management During the COVID-19 Pandemic: A Multinational Consensus Statement From the Fleischner Society

The Journal of Cardiovascular Computed Tomography: 2020 Year in review

COVID Research Group of Lariboisiere Hospital. Coronary Artery Calcification and Complications in Patients With COVID-19

Subclinical coronary artery disease in COVID-19 patients

Impact of clinical and subclinical coronary artery disease as assessed by coronary artery calcium in COVID-19

COVID-19 pandemic and cardiac imaging: EACVI recommendations on precautions, indications, prioritization, and protection for patients and healthcare personnel

COVID-19 and Cardiovascular Disease. Circulation

Vulnerable Plaques Producing an Acute Coronary Syndrome Exhibit a Different CT Phenotype than Those That Remain Silent

Management of Acute Myocardial Infarction During the COVID-19 Pandemic: A Position Statement From the Society for Cardiovascular Angiography and Interventions (SCAI), the American College of Cardiology (ACC), and the American College of Emergency Physicians (ACEP)

The European Society for Cardiology. ESC Guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic

Coronary CT Angiography in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome

Long-term health outcomes and cost-effectiveness of coronary CT angiography in patients with suspicion for acute coronary syndrome

Role of multimodality imaging in evaluation of cardiovascular involvement in COVID-19

Myocardial Late Iodine Enhancement and Extracellular Volume Quantification with Dual-Layer Spectral Detector Dual-Energy Cardiac CT

Myocardial Delayed Enhancement CT for the Evaluation of Heart Failure: Comparison to MRI

Quadruple rule out" with cardiac computed tomography in COVID-19 patient with equivocal acute coronary syndrome presentation

Role of computed tomography in COVID-19

Myocardial injury in COVID-19: The role of coronary computed tomography angiography (CTA)

COVID-19 pathways for brain and heart injury in comorbidity patients: A role of medical imaging and artificial intelligence-based COVID severity classification: A review

State-of-the-Art Deep Learning in Cardiovascular Image Analysis

The present and future of deep learning in radiology

A fully automatic deep learning system for COVID-19 diagnostic and prognosticanalysis

Six artificial intelligence paradigms for tissue characterisation and classification of non-COVID-19 pneumonia against COVID-19 pneumonia in computed tomography lungs

Using Artificial Intelligence to Detect COVID-19 and Community-acquired Pneumonia Based on Pulmonary CT: Evaluation of the Diagnostic Accuracy

The Role of Imaging in the Detection and Management of COVID-19: A Review

Deep learning analysis in coronary computed tomographic angiography imaging for the assessment of patients with coronary artery stenosis

Performance of a deep learning algorithm for the evaluation of CAD-RADS classification with CCTA

Detecting human coronary inflammation by imaging perivascular fat

Epicardial adipose tissue is associated with extent of pneumonia and adverse outcomes in patients with COVID-19

Clinical and radiographic features of cardiac injury in patients with 2019 novel coronavirus pneumonia

Maurovich-Horvat P. Cardiac Computed Tomography Radiomics: A Comprehensive Review on Radiomic Techniques

Radiotranscriptomic analysis of perivascular adipose tissue quantifies vascular inflammation in COVID-19 from toutine CT angiograms: stratification of "new UK variant" infection and prediction of in-hospital outcomes

A Novel CT-derived Radiotranscriptomic Signature of Perivascular Adipose Tissue Stratifies COVID-19 Vascular Cytokine Burst and Predicts in Hospital Outcomes

Artificial Intelligence (AI) applications for COVID-19 pandemic

Systemic Inflammation and COVID-19 Mortality in Patients with Major Noncommunicable Diseases: Chronic Coronary Syndromes, Diabetes and Obesity

Standardized reporting systems for computed tomography coronary angiography and calcium scoring: A real-world validation of CAD-RADS and CAC-DRS in patients with stable chest pain

Screening for cardiovascular disease risk using traditional risk factor assessment or coronary artery calcium scoring: the ROBINSCA trial

Società Italiana di Cardiologia and the CCU Academy investigators group. Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era

Society of Cardiovascular Computed Tomography guidance for use of cardiac computed tomography amidst the COVID-19 pandemic Endorsed by the American College of Cardiology

EAPCI Position Statement on Invasive Management of Acute Coronary Syndromes during the COVID-19 pandemic